[go: up one dir, main page]

WO2011111066A3 - Composition and uses thereof - Google Patents

Composition and uses thereof Download PDF

Info

Publication number
WO2011111066A3
WO2011111066A3 PCT/IN2011/000154 IN2011000154W WO2011111066A3 WO 2011111066 A3 WO2011111066 A3 WO 2011111066A3 IN 2011000154 W IN2011000154 W IN 2011000154W WO 2011111066 A3 WO2011111066 A3 WO 2011111066A3
Authority
WO
WIPO (PCT)
Prior art keywords
hypertriglyceridemia
hyperglycemia
prophylaxis
diabetes
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2011/000154
Other languages
French (fr)
Other versions
WO2011111066A2 (en
Inventor
Mathiyazhagan Rengaswamy
Tisha Banerjee
Jagannath Madanahalli Ranganath Rao
Anup Mammen Oommen
Srinivas Ramchandra Sidgiddi
Venkataranganna Marikunte Venkata Narasappa
Sridhar Tirumalai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Connexios Life Sciences Pvt Ltd
Original Assignee
Connexios Life Sciences Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Connexios Life Sciences Pvt Ltd filed Critical Connexios Life Sciences Pvt Ltd
Publication of WO2011111066A2 publication Critical patent/WO2011111066A2/en
Publication of WO2011111066A3 publication Critical patent/WO2011111066A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates generally to pharmaceutical compositions and their use for the prophylaxis or treatment of conditions associated with hyperglycemia or hypertriglyceridemia, including (but not limited to), diabetes (e.g., Type 2 diabetes) and obesity. The present invention also relates to methods of prophylaxis or treatment of such conditions, based on the finding that an inhibitor of a phosphodiesterase 3 activity and an inhibitor of angiotensin receptor activity provide a desirable synergistic effect on hyperglycemia and hypertriglyceridemia.
PCT/IN2011/000154 2010-03-12 2011-03-09 Composition and uses thereof Ceased WO2011111066A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN664/CHE/2010 2010-03-12
IN664CH2010 2010-03-12
US32994410P 2010-04-30 2010-04-30
US61/329,944 2010-04-30

Publications (2)

Publication Number Publication Date
WO2011111066A2 WO2011111066A2 (en) 2011-09-15
WO2011111066A3 true WO2011111066A3 (en) 2012-03-29

Family

ID=44563940

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2011/000154 Ceased WO2011111066A2 (en) 2010-03-12 2011-03-09 Composition and uses thereof

Country Status (1)

Country Link
WO (1) WO2011111066A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO3034071T3 (en) * 2011-12-21 2018-05-05
EP2825159B1 (en) 2012-03-15 2022-06-22 Boehringer Ingelheim Vetmedica GmbH Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
KR20240006511A (en) 2021-05-11 2024-01-15 리제너론 파마슈티칼스 인코포레이티드 How to Treat Liver Disease Using Phosphodiesterase 3B (PDE3B) Inhibitors

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830909A (en) * 1993-06-28 1998-11-03 American Cyanamid Company Angiotensin (AII) antagonists as inhibitors of the growth of adipose tissue
US5981470A (en) * 1994-06-07 1999-11-09 The University Of Birmingham Uterine fibroid treatment
US20070208029A1 (en) * 2005-10-21 2007-09-06 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20080004283A1 (en) * 2005-12-06 2008-01-03 Menarini Ricerche S.P.A. Pharmaceutical Compositions for the Treatment of Cellulite
US20080167291A1 (en) * 2006-05-09 2008-07-10 Braincells, Inc. Neurogenesis by modulating angiotensin

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830909A (en) * 1993-06-28 1998-11-03 American Cyanamid Company Angiotensin (AII) antagonists as inhibitors of the growth of adipose tissue
US5981470A (en) * 1994-06-07 1999-11-09 The University Of Birmingham Uterine fibroid treatment
US20070208029A1 (en) * 2005-10-21 2007-09-06 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20080004283A1 (en) * 2005-12-06 2008-01-03 Menarini Ricerche S.P.A. Pharmaceutical Compositions for the Treatment of Cellulite
US20080167291A1 (en) * 2006-05-09 2008-07-10 Braincells, Inc. Neurogenesis by modulating angiotensin

Also Published As

Publication number Publication date
WO2011111066A2 (en) 2011-09-15

Similar Documents

Publication Publication Date Title
WO2009089494A3 (en) Pharmaceutical compositions
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
MY148496A (en) Dpp iv inhibitor formulations
EA033343B1 (en) Compounds inhibiting rip2 kinase, pharmaceutical composition based thereon and use thereof for the treatment of diseases mediated by rip2 kinase
PH12013501136A1 (en) Lysophosphatidic acid receptor antagonists and uses thereof
MX2009007944A (en) Compounds and compositions as kinase inhibitors.
IN2012DN02177A (en)
IN2012DN02730A (en)
IN2012DN00754A (en)
GB0906579D0 (en) Pharmaceuticals, compositions and methods of making and using the same
MX338489B (en) Hydantoin derivatives useful as kv3 inhibitors.
WO2008070268A3 (en) Pharmaceutical compositions
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
TN2012000081A1 (en) Compounds and compositions as protein kinase inhibitors
IN2012DN01233A (en)
IN2012DN00624A (en)
WO2008097428A3 (en) Compounds and compositions as modulators of gpr119 activity
MX2012002366A (en) Novel pyrrolidine derived beta 3 adrenergic receptor agonists.
CL2012001043A1 (en) Compounds derived from hexahydroindenopyridine and / or octahydrobenzoquinoline, inhibitors of 11ß-hydroxysteroid dehydrogenase 1 (hsd 1); pharmaceutical compositions comprising the compounds; and use of the compounds for the preparation of medicaments for the treatment of metabolic disorders.
IN2012DN02471A (en)
WO2008079610A3 (en) Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
AU2011279845A8 (en) Novel pyrrolidine derived beta 3 adrenergic receptor agonists
WO2011111066A3 (en) Composition and uses thereof
WO2016168388A3 (en) Therapies for obesity, diabetes and related indications
WO2010042212A3 (en) Methods for treating or preventing pain using spicamycin derivatives

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11752948

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 7859/CHENP/2012

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11752948

Country of ref document: EP

Kind code of ref document: A2